Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem

Health Economics

Volumn 5, Issue 4, 1996, Pages 297-305

  Willan, Andrew R ^a   O'Brien, Bernie J ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

CEA; Confidence intervals; Cost effectiveness ratio; Fieller's theorem

Indexed keywords

ARTICLE; CLINICAL TRIAL; COMPUTER SIMULATION; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH SERVICES RESEARCH; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL MODEL; STATISTICS;

COMPUTER SIMULATION; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; HEALTH SERVICES RESEARCH; HUMANS; MODELS, ECONOMIC; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SAMPLE SIZE; STOCHASTIC PROCESSES;

EID: 0030179629     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T     Document Type: Review

References (26)

1. Detsky, A. S. A guideline for preparation of economic analysis of pharamacetical products: A draft document for Ontario and Canada. Pharmacoeconomics 1993; 3: 354-361.
2. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: Including submissions involving economic analyses. Woden (ACT): Department of Health, Housing and Community Services, 1990.
3. Leaf, A. Cost effectiveness as a criterion for Medicare coverage. New England Journal of Medicine 1989; 321: 898-900.
4. Drummond, M. F., Stoddart, G. L. and Torrance, G. W. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
5. Luce, B. R. and Elixhauser, A. Standards for socio-economic evaluations of health care products and services, Berlin: Springer, 1990.
6. L'Abbe, K. A., Detsky, A. S. and O'Rourke, K. Meta-analysis in clinical research. Annals of Internal Medicine 1987; 107: 224-233.
7. Drummond, M. F. and Davies, L. M. Economic analysis alongside clinical trials: revisiting the methodological issues. International Journal of Technology Assessment in Health Care 1991; 7: 561-573.
8. Adams, M. E., McCall, N. T., Gray, D. T., Orza, M. J. and Chalmers, T. C. Economic analysis in randomized control trials. Medical Care 1992; 30: 231-243.
9. O'Brien, B. J., Drummond, M. F., Labelle, R.J. and Willan, A. R. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in heath care. Medical Care 1994; 32: 150-163.
10. Van Hout, B. A., Al, M. J., Gordon, G. S. and Rutten, F. F. H. Costs, effects and C/E-ratios alongside a clinical trial. Health Economics 1994; 3: 309-319.
11. Weinstein, M. C. and Stason, W. B. Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine 1977; 296: 716-721.
12. Doubilet, P., Weinstein, M. C. and McNeil, B. J. Use and misuse of the term 'cost-effective' in medicine. New England Journal of Medicine 1986; 314: 253-255.
13. Edelson, J. T., Weinstein, M. C., Tosteson, A. N. A., Williams, L., Lee, T. H. and Goldman, L. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. Journal of the American Medical Association 1990; 263: 407-413.
14. Torrance, G. and Feeny, D. Utilities and quality-adjusted life-years. International Journal of Technology Assessment in Health Care 1989; 5: 559-575.
15. Drummond, M., Torrance, G. and Mason, J. Cost-effectiveness league tables: More harm than good? Social Science and Medicine 1993; 37, 33-40.
16. Laupacis, A., Feeny, D., Detsky, A. and Tugwell, P. How attractive does a new technology have to be to warrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal 1992; 146: 473-481.
17. Anderson, J. P., Bush, J. W., Chen, M. and Dolenc, M. Policy space areas and properties of benefit-cost/utility analysis. Journal of the American Medical Association 1986; 255: 794-795.
18. Black, W. C. The CE plane: a graphic representation of cost-effectiveness. Medical Decision Making 1990; 10: 212-214.
19. Gafni, A. and Birch, S. Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid them. Canadian Medical Association Journal 1993; 148: 913-917.
20. Weinstein, M. C. and Fineburg, H. V. Clinical decision analysis. Philadelphia: W. B. Saunders, 1980.
21. Doubilet, P., Begg, C. B., Weinstein, M. C., Braun, P. and McNeil, B. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Medical Decision Making 1985; 5: 157-177.
22. Efron, B. and Gong, G. A leisurely look at the Bootstrap, Jackknife and cross-validation. The American Statistician 1983; 37: 36-48.
23. Shapiro, S. S. and Wilk, M. B. An analysis of variance test for normality (complete samples). Biometrika 1965, 52: 591-611.
24. Willan, A. R. Power function arguments in support of an alternative approach for analysing management trials. Controlled Clinical Trials 1994; 15: 211-219.
25. Efron, B. Bootstrap confidence intervals for a class of parametric problems. Biometrika 1985; 72: 45-58.
26. Fieller, E. C. Some problems in interval estimation with discussion. Journal of the Royal Statistical Society, Series B 1954; 16: 175-185.